Photo of Elizabeth Nevins

Elizabeth Nevins

Subscribe to Elizabeth Nevins's Posts

Elizabeth Nevins is an associate in the Corporate Practice Group in the firm's Dallas office, and a member of the Healthcare team.

Contact:Read more about Elizabeth Nevins

The Federal Trade Commission (“FTC”) has turned the antitrust lens inward, examining and recommending removal or revision of federal regulations it deems as potential barriers to entry and innovation. In a letter to the Office of Management and Budget (“OMB”) dated September 16, 2025, Chairman Andrew N. Ferguson identified more than 125 regulations that, in his view, restrict entry, entrench incumbents, or otherwise distort competition (the “Ferguson Letter”). The recommendations were issued pursuant to Executive Order 14267, which directs agencies to reduce anticompetitive regulatory barriers.Continue Reading FTC Recommends Rollback of Anticompetitive Regulations

On July 24, 2025, the Federal Trade Commission (“FTC”) and the U.S. Department of Justice (“DOJ”) convened the second of three public listening sessions aimed at identifying barriers to drug price competition in the U.S. healthcare system. The session is part of a broader policy push under Executive Order 14273, “Lowering Drug Prices by Once Again Putting Americans First,” which mandates a coordinated federal effort to investigate and dismantle anticompetitive practices within the pharmaceutical sector, with the overarching goal of reducing prescription drug costs for Americans. The July 24th session concentrated on issues relating to formulary design, benefit management, and the misuse of regulatory mechanisms that may restrict or delay generic and biosimilar market entry.Continue Reading DOJ and FTC Host Second Session on Structural and Regulatory Impediments to Drug Competition

President Trump was sworn into office on Monday, promising swift action on several fronts. There is already a new Federal Trade Commission (“FTC”) Chair, Andrew Ferguson, with former FTC Chair Lina Khan expected to step down shortly. At the Department of Justice, Antitrust Division (“DOJ”), proposed AAG Gail Slater will need to be confirmed by the Senate before she can take the helm.Continue Reading Looking Back and Looking Forward: Healthcare Antitrust in a New Administration: What Stays the Same and What Changes?